BMS-279700 is a potent oral activity inhibitor that is part of a new family of aniline 5-azimidazolaquoxaline analogs and has excellent anti-inflammatory activity in vivo, as well as in vitro activity against p56LCK and T cell proliferation, blocking the
BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor. With Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 shows hypertensive effects[1].
BMS-243117 is an effective selective LCK inhibitor with good cell activity (IC(50)=1.1 microM) and inhibition of T cell proliferation, which has great potential for therapeutic immunosuppression and the treatment of diseases such as rheumatoid arthritis a
BMS-247243 is a novel cephalosporin inhibitor that is mainly active against Gram-positive bacteria and also against methicillin-resistant Staphylococcus.
BMS-284640 is a Na(+) H(+) exchange agent (NHE) inhibitor that has provided substantial protection in various animal models of myocardial ischemia (MI) and reperfusion in preclinical studies.
BMS-214662 is a Farnesyltransferase inhibitor , is also a nonsedating benzodiazepine derivative with potential antineoplastic activity. BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.